CJC-1295 for Recovery: What Women Need to Know Before Trying It

What Is CJC-1295 and Why Do Women Use It Off-Label?

CJC-1295 is a synthetic analogue of the first 29 amino acids of endogenous growth-hormone-releasing hormone (GHRH), modified at four positions to extend its half-life from roughly 7 minutes to 6 to 8 days. The modification is why it is sometimes called "modified GRF 1-29" or "mod GRF 1-29," names you will see used interchangeably on compounding pharmacy sites.

No pharmaceutical company has submitted CJC-1295 for FDA approval for any indication. The FDA-approved GHRH analogue in clinical use is sermorelin, which has a much shorter half-life and carries a narrower but documented safety record. CJC-1295 sits in a regulatory grey zone: it is synthesized and sold through compounding pharmacies as an "investigational peptide," outside the oversight chain that governs purity, potency, and sterility.

Women seek it for several reasons.

The Recovery Appeal

The logic is pharmacologically coherent, even if the evidence is thin. Growth hormone (GH) drives tissue repair through insulin-like growth factor-1 (IGF-1), which stimulates collagen synthesis, satellite cell activation in skeletal muscle, and cartilage remodeling. A 2006 clinical pharmacology study published in the Journal of Clinical Endocrinology and Metabolism showed that CJC-1295 doses of 30 to 60 mcg/kg in healthy adults produced sustained elevations in serum GH and IGF-1 for up to 14 days, with no serious adverse events in that short window.

The jump from "raises IGF-1" to "speeds your recovery from a torn ACL or a marathon" is large and not validated by outcome-level data in women.

Where Women's GH Physiology Is Different

Women have higher baseline GH secretory frequency than men across all reproductive stages, and estrogen amplifies GH pulse amplitude. After menopause, both GH pulse amplitude and IGF-1 fall sharply, a change that mirrors the accelerated loss of lean mass and bone mineral density seen in postmenopausal women. This biological reality is part of why peptide-therapy marketers target perimenopausal and postmenopausal women specifically, even though that population has the least trial data on CJC-1295 specifically.

What the Evidence Actually Shows (and Where It Stops)

The evidence base for CJC-1295 in recovery is best described as mechanistic-to-early-clinical. It does not yet extend to controlled outcomes trials in women.

Human Trial Data

The foundational human pharmacology work comes from Alba et al. (2006), which enrolled 65 healthy adults (mean age 35, sex breakdown not stratified in the published results) in a double-blind, placebo-controlled dose-escalation study. After a single subcutaneous injection, CJC-1295 at 60 mcg/kg increased mean IGF-1 levels by 44 to 55 percent above baseline and maintained that increase for six to eight days. GH AUC increased two- to threefold. These are the numbers most cited by peptide-prescribing clinicians.

What the same study did not show: any functional recovery metric, any musculoskeletal endpoint, or any sex-stratified pharmacokinetics. The trial duration was too short to assess safety beyond acute injection-site reactions.

No published randomized controlled trial has evaluated CJC-1295 specifically for tissue recovery, injury healing, or post-surgical rehabilitation in any sex. The evidence grade for "CJC-1295 improves recovery" sits at GRADE D: extrapolated from mechanism and surrogate markers, not patient-important outcomes.

What We Can Borrow (With Caution) From GH and IGF-1 Research

Recombinant human GH (rhGH), which is FDA-approved for adult GH deficiency, has demonstrated improvements in lean body mass, bone mineral density, and exercise capacity in women with documented GHD in multiple controlled trials. The relevant caution: rhGH is dosed under serum GH and IGF-1 monitoring, starting at 0.1 to 0.2 mg/day in women (lower than men because estrogen reduces hepatic IGF-1 sensitivity), titrated up based on labs and symptoms per Endocrine Society guidelines.

CJC-1295 bypasses that precision entirely. You are stimulating endogenous GH production without measuring how much is being produced or whether IGF-1 lands in a safe range.

A framework for thinking about the evidence gap by life stage:

| Life Stage | GH Axis Baseline | IGF-1 Sensitivity | Evidence Specifically in This Group | |---|---|---|---| | Reproductive years (18-40) | Normal to high pulse frequency | Normal | None for CJC-1295; limited rhGH data | | Perimenopause (40-51) | Declining pulse amplitude | Declining | None | | Post-menopause | Low amplitude, low IGF-1 | Low, but receptors upregulated | None | | PCOS (any age) | Variable, often elevated LH/GH ratio | Often elevated | None; IGF-1 hypersensitivity is a concern | | TTC / Pregnant | See pregnancy section below | N/A | Contraindicated |

Sex-Specific Risks Women Need to Know

Estrogen Changes Your Risk Profile

Estrogen stimulates GH secretion and simultaneously reduces hepatic IGF-1 production per unit of GH stimulus, a phenomenon called "GH resistance at the liver." This is why premenopausal women on oral estrogen (including combined oral contraceptives) need higher GH doses to achieve equivalent IGF-1 levels compared to men or postmenopausal women. The clinical consequence for CJC-1295 use: a woman on the pill who injects CJC-1295 may generate high GH levels but blunted IGF-1 response, while a postmenopausal woman off estrogen may get the same GH stimulus but a much larger IGF-1 spike, raising her risk of adverse IGF-1-mediated effects.

IGF-1 and Cancer Risk

Elevated IGF-1 is associated with increased risk of breast, ovarian, and endometrial cancer in women. A 2004 meta-analysis in Lancet Oncology found that women in the highest quartile of circulating IGF-1 had a relative risk of premenopausal breast cancer approximately 1.65 times that of women in the lowest quartile. This does not prove that transient CJC-1295-induced IGF-1 elevations cause cancer, but it is a clinically material signal for women with BRCA variants, strong family history, or existing hormone-sensitive conditions.

The American Society of Clinical Oncology advises against GH use in patients with active malignancy or recent history of malignancy. That caution applies proportionally to GH secretagogues including CJC-1295.

PCOS: A Particular Caution

Women with PCOS already have dysregulated GH pulsatility and often elevated IGF-1 activity relative to GH levels, driven in part by hyperinsulinemia. Stimulating the GH axis further with CJC-1295 may worsen insulin resistance or amplify androgen production (since IGF-1 potentiates ovarian theca cell androgen synthesis). No trial has studied CJC-1295 in women with PCOS. Until that data exists, use in this group should be considered especially high-risk.

Fluid Retention and the Menstrual Cycle

GH and IGF-1 both promote renal sodium retention. Some women using CJC-1295 report bloating and breast tenderness that tracks with their cycle, likely because GH-driven fluid retention adds to the progesterone-driven fluid shifts of the luteal phase. This is anecdotal, but physiologically plausible and worth monitoring if you proceed.

Other Adverse Effects

In the Alba et al. Trial, the most common adverse events were injection-site reactions (pain, redness) in roughly 30 percent of participants, transient flushing, and headache. Carpal tunnel syndrome, joint pain (arthralgias), and peripheral edema are known class effects of GH-axis stimulation and have been documented with rhGH use in adults. Because CJC-1295 produces prolonged GH elevation (days, not hours), these effects may be more sustained than with shorter-acting secretagogues.

Pregnancy, Lactation, and Contraception: A Required Caution

CJC-1295 is contraindicated in pregnancy.

There is no published human safety data on CJC-1295 exposure during pregnancy. Animal studies of GHRH analogues show that supraphysiologic GH-axis stimulation during organogenesis disrupts fetal growth plate development and alters placental IGF-1 signaling. CJC-1295 has not been assigned a formal FDA pregnancy category because it has never been reviewed for approval, which itself is a warning sign: there is no regulatory body watching this drug's use.

If you are trying to conceive, CJC-1295 should be stopped before attempting pregnancy. Because the drug extends GH elevation for up to two weeks per injection, a washout period of at least four to six weeks is prudent before conception attempts, though no pharmacokinetic data in pregnancy defines an exact safe interval.

Lactation: Transfer of CJC-1295 into human breast milk is unknown. GH itself does not substantially transfer into breast milk at physiologic levels, but synthetic GHRH analogues have not been studied in lactating women. The conservative and correct recommendation is to avoid CJC-1295 entirely during breastfeeding.

Contraception: Any woman of reproductive age using CJC-1295 should use reliable contraception for the duration of use and for at least one full menstrual cycle (minimum four weeks) after stopping. Given the peptide's extended half-life, two full cycles of washout is a safer standard.

Women with a history of estrogen-sensitive conditions (ER-positive breast cancer, endometriosis, hormone-sensitive fibroids) should discuss GH-axis peptide use with their oncologist or gynecologist before starting, not after.

Who This May Be Right For (and Who It Is Not Right For)

Potentially Lower-Risk Candidates

This is a narrow group. A woman who might have the most defensible rationale for exploring CJC-1295 with a physician would be:

• A postmenopausal woman with documented low IGF-1 on serum testing (below the age-adjusted reference range).
• No personal or first-degree family history of breast, ovarian, or endometrial cancer.
• No active PCOS, insulin resistance, or fibroids.
• Not on oral estrogen (which complicates IGF-1 interpretation).
• Willing to monitor IGF-1 levels at baseline, 30 days, and 90 days.
• Working with a clinician who can adjust or stop the peptide based on lab results.

Even in this group, the off-label status means informed consent should include an explicit acknowledgment that long-term safety is unknown.

High-Risk or Contraindicated Groups

The following women should not use CJC-1295:

• Pregnant or planning to become pregnant within two months.
• Breastfeeding.
• Personal history of any malignancy, particularly hormone-sensitive cancers.
• Active or suspected acromegaly or pituitary tumor.
• Uncontrolled type 2 diabetes or significant insulin resistance (IGF-1 worsens glycemic control).
• PCOS with hyperandrogenism or hyperinsulinemia (until specific data exists).
• Women on tamoxifen, aromatase inhibitors, or other endocrine cancer therapies.
• Women with active thyroid disease (GH stimulation accelerates peripheral T4-to-T3 conversion and can destabilize thyroid status in women with autoimmune thyroiditis).

The Compounding Problem: What You Are Actually Injecting

CJC-1295 is not manufactured under FDA's Good Manufacturing Practice (GMP) standards because it is not an approved drug. Compounding pharmacies that produce it operate under 503A or 503B exemptions intended for patient-specific preparations, not mass-produced investigational peptides. A 2018 FDA analysis of compounded peptide products found that compounded drugs are not tested for sterility, potency, or identity with the same rigor as approved pharmaceuticals.

Independent testing of compounded GH-releasing peptides purchased in the United States has found wide batch-to-batch variability in peptide concentration, with some products containing less than 70 percent of labeled potency and others containing unknown impurities. You may be injecting something close to what you think, or something quite different.

This is not a reason to assume every compounding pharmacy is reckless, but it is a reason to ask your pharmacy for a certificate of analysis (COA) from a third-party analytical lab before injecting anything.

Dosing Protocols Cited in the Literature and Clinical Practice

No FDA-approved dosing exists for CJC-1295. The doses used in Alba et al. (2006) ranged from 30 to 60 mcg/kg subcutaneously as single injections. In off-label clinical practice, compounding prescribers commonly use 100 to 300 mcg subcutaneously, two to three times per week, often combined with a GHRP (growth hormone-releasing peptide) such as ipamorelin.

The combination of CJC-1295 plus ipamorelin is marketed as producing a more "physiologic" GH pulse, though no peer-reviewed trial has tested this combination in women for any endpoint.

Women should note that because estrogen status changes GH sensitivity and IGF-1 response (as described above), the same dose will not produce the same serum effect across different life stages or hormonal contexts. A dose appropriate for a 45-year-old perimenopausal woman on progesterone-only therapy could produce excessive IGF-1 elevation in a postmenopausal woman not on any hormone therapy.

Baseline and follow-up serum IGF-1 testing (and ideally fasting insulin, HbA1c, and a thyroid panel) should be considered the minimum monitoring standard if you proceed, following the general framework used for adult GH therapy monitoring per Endocrine Society clinical practice guidelines.

What Honest Shared Decision-Making Looks Like

"CJC-1295 for recovery" is a real conversation happening in telehealth practices, functional medicine offices, and sports-medicine clinics across the country. The women asking about it are not naive. They are often high-functioning, physically active, and frustrated with the recovery limitations that come with perimenopause or a demanding athletic schedule.

The honest version of this conversation has several components.

First, the mechanism is real: the GH-IGF-1 axis does drive tissue repair, and women's GH axis does decline with age. Second, no trial has demonstrated that CJC-1295 specifically improves any recovery outcome in women, or in anyone. Third, the risks, especially around breast cancer, PCOS, and pregnancy, are clinically meaningful even if they are not definitively proven at CJC-1295 doses. Fourth, the product you inject from a compounding pharmacy may not be what the label says.

The Endocrine Society's position on growth hormone use in normal aging adults, published in the Journal of Clinical Endocrinology and Metabolism, states: "We recommend against the use of GH for anti-aging or performance enhancement in healthy adults." That position covers GH secretagogues by extension, even if it does not name CJC-1295 specifically.

If your recovery is genuinely suffering, the causes are more often addressable with evidence-based interventions: optimizing sleep (where the GH secretagogue story is at least plausible), correcting iron deficiency (common in premenopausal women and a top driver of fatigue and poor adaptation), evaluating thyroid function, assessing whether estrogen or progesterone replacement is appropriate for your life stage, and examining your training load relative to your caloric and protein intake.

A serum IGF-1 level drawn as part of a comprehensive metabolic workup will tell you whether your GH axis is genuinely suppressed before you decide to stimulate it further with an unregulated peptide. Start there.